Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Icagen
Durham, North Carolina, United States
- Ownership
- Public · ICGN
- Employees
- ~37
- Development stage
- Preclinical
01
Overview
Icagen is a drug discovery company specializing in ion channel and transporter targets. It offers integrated Target-to-lead services using proprietary technologies such as the XRpro platform. The company has advanced small molecule candidates into Phase 1 trials for epilepsy, neuropathic pain, and asthma. Most work is early-stage or preclinical, with ongoing collaborations with major pharma partners.
- Therapeutic areas
- PulmonologyNeurologyRheumatology
- Modalities
- Small moleculesTherapeutic antibodies
- Industry
- Biotech
02
Partnerships
Bristol‑Myers Squibb CompanyAstellas Pharma Inc.Pfizer Inc.
Beyond the preview
Go deeper on Icagen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Icagen.